Drug intelligence / Profile preview

NNC0113-5840

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC0113-5840 is a long-acting peptide analogue of glucose-dependent insulinotropic polypeptide (GIP) developed by Novo Nordisk. It acts as a selective GIP receptor agonist. While Novo Nordisk is well-known for its GLP-1 receptor agonists (like semaglutide), NNC0113-5840 represents an exploration into GIP-specific signaling or potential use in future combinations for weight management. It is currently in Phase 1 clinical development for the treatment of obesity and overweight, administered via subcutaneous injection to evaluate safety, tolerability, and pharmacokinetics.

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on NNC0113-5840.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0113-5840.

Explore the full profile